This story has been updated from a previous version.
NEW YORK, April 11 – Incyte Genomics said Wednesday it had licensed two patents to Merck that will allow the pharmaceutical company to manufacture microarrays using a patented non-PCR method for RNA amplification.
The patents, numbers 5,716,785 and 5,891,636, cover the use of a non-PCR-based RNA amplification technology, allowing researchers to create gene expression information by linearly increasing RNA samples from cellular mRNA.
"We are pleased that Merck is one of a growing list of companies that have recognized the value of our proprietary technology to maximize the effectiveness of their highly developed microarray based gene expression and internal microarray manufacture programs," Roy Whitfield, CEO of Incyte, said in a statement.
Incyte has exclusive licenses to the patents, which it acquired from Layton Bioscience.
Merck was not immediately available to comment on the decision to license the patents. Investment Bank Dain Rauscher Wessels said in a morning report that it expected Merck to use the licenses to produce medium- and low-density microarrays for use in its internal drug discovery and development program.
Financial terms of the deal were not disclosed.